Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

Senior Biden Food and Drug Administration (FDA) officials spent weeks casting doubt on reports of cardiac risks associated with the ...

According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease mechanisms have yielded new diagnostic ...

DelveInsight's Cancer Pain Market Insights report includes a comprehensive understanding of current treatment practices, ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday.

What was holding up a deal appeared to be the lack of affordable units, as a previous proposal called for 420. However, NYC's ...

PUNE, India, June 11, 2025 /PRNewswire/ — According to the latest report published by Credence Research, Inc., the global ...

(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune ...

"The good news is we've got a lot of interest — a lot of interest," Starbucks CEO Brian Niccol told the FT. KKR & Co, ...